中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2308-2312

Prognosis and adverse reactions of patients with acute-on-chronic liver failure receiving artificial liver support therapy stratified by international normalized ratio

DOI: 10.3969/j.issn.1001-5256.2022.10.020

  • Department of Severe Liver Disease, The Ninth Hospital of Nanchang, Nanchang 330002, China

Research funding:

Science and Technology Project of Health Commission of Jiangxi Province in 2021 (202140131)

More Information
  • Corresponding author: XIONG Molong, xml86005@163.com(ORCID: 0000-0003-4701-6002)
  • Received Date: 2022-02-15
  • Accepted Date: 2022-03-20
  • Published Date: 2022-10-20
    Abstract
  •   Objective  To investigate the prognosis and adverse reactions of patients with acute-on-chronic liver failure (ACLF) receiving artificial liver support therapy stratified by international normalized ratio (INR).  Methods  A total of 515 ACLF patients who received artificial liver support therapy in Department of Severe liver Disease, The Ninth Hospital of Nanchang, from January 2010 to May 2020 were enrolled, and according to the level of INR, they were divided into group A with 20 patients (INR < 1.5), group B with 115 patients (1.5≤INR < 1.9), group C with 179 patients (1.9≤INR < 2.6), group D with 61 patients (2.6≤INR < 3.2), group E with 75 patients (3.2≤INR < 4.2), and group F with 65 patients (INR≥4.2). All patients received multimodality medical treatment combined with artificial liver support therapy. The one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups。The chi-square test was used for comparison of categorical data between groups. Bonferroni correction was used for further comparison between two groups. and the receiver operating characteristic (ROC) curve was used to evaluate the value of INR and MELD scoring system in predicting the prognosis of ACLF patients.  Results  As for 90-day mortality rate, there was a significant difference between the six groups stratified by INR (χ2=124.84, P < 0.001); there was no significant difference between groups A(25%), B(25.2%), and C(39.7%) (P > 0.05), and there was a significant difference between groups D/E/F(65.6%, 82.7%, and 92.3%, respectively) and groups A/B/C (all P < 0.05); there was no significant difference between groups D and E and between groups E and F (P > 0.05), and there was a significant difference between groups D and F (P < 0.05). There was no significant difference in the incidence rate of intraoperative adverse reactions between the six groups (χ2=8.956, P=0.111). INR had an area under the ROC curve of 0.786 (95% confidence interval: 0.746-0.825, P < 0.001) in predicting the prognosis of patients with ACLF receiving artificial liver support therapy, with a sensitivity of 66.7% and a specificity of 79.8%.  Conclusion  INR has a good value in predicting the prognosis of ACLF patients receiving artificial liver support therapy, and the artificial liver has good safety.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    XIAO LL, XU XW, HUANG KZ, et al. Artificial liver support system improves short-term outcomes of patients with HBV-associated acute-on-chronic liver failure: A propensity score analysis[J]. Biomed Res Int, 2019, 2019: 3757149. DOI: 10.1155/2019/3757149.
    [3]
    FAN Q, LI Z. Liver transplantation for acute-on-chronic liver failure[J]. Ogran Transplant, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.

    范祺, 李照. 慢加急性肝衰竭的肝移植治疗[J]. 器官移植, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.
    [4]
    ALSHAMSI F, ALSHAMMARI K, BELLEY-COTE E, et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials[J]. Intensive Care Med, 2020, 46(1): 1-16. DOI: 10.1007/s00134-019-05783-y.
    [5]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [7]
    PORTE RJ, LISMAN T, TRIPODI A, et al. The International Normalized Ratio (INR) in the MELD score: problems and solutions[J]. Am J Transplant, 2010, 10(6): 1349-1353. DOI: 10.1111/j.1600-6143.2010.03064.x.
    [8]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437. DOI: 10.1053/j.gastro.2013.02.042.
    [9]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [10]
    RUESCHENBAUM S, CIESEK S, QUECK A, et al. Dysregulated adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure[J]. Front Immunol, 2021, 11: 534731. DOI: 10.3389/fimmu.2020.534731.
    [11]
    ZHANG CX, GENG JW, XIE Q. Global disease burden and regional differences of acute-on-chronic liver failure: a review[J]. Chin Hepatol, 2021, 26(4): 355-358. DOI: 10.3969/j.issn.1008-1704.2021.04.003.

    张宸溪, 耿嘉蔚, 谢青. 慢加急性肝衰竭全球疾病负担及地域性差异研究进展[J]. 肝脏, 2021, 26(4): 355-358. DOI: 10.3969/j.issn.1008-1704.2021.04.003.
    [12]
    YADAV SK, SARAF N, CHOUDHARY NS, et al. Living donor liver transplantation for acute-on-chronic liver failure[J]. Liver Transpl, 2019, 25(3): 459-468. DOI: 10.1002/lt.25395.
    [13]
    DU FJ, SHAO C, ZHENG GZ. Therapeutic effect and nursing observation of artificial liver plasma replacement in severe hepatitis[J]. J Changchun Univ Chin Med, 2020, 36(2): 381-384. DOI: 10.13463/j.cnki.cczyy.2020.02.051.

    杜粉静, 邵灿, 郑鸽之. 人工肝血浆置换术在重症肝炎中的治疗效果及护理[J]. 长春中医药大学学报, 2020, 36(2): 381-384. DOI: 10.13463/j.cnki.cczyy.2020.02.051.
    [14]
    NOVELLI G, ANNESINI MC, MORABITO V, et al. Cytokine level modifications: molecular adsorbent recirculating system versus standard medical therapy[J]. Transplant Proc, 2009, 41(4): 1243-1248. DOI: 10.1016/j.transproceed.2009.03.035.
    [15]
    XU KL, LEI M, YUAN WF, et al. Effect of dual plasma molecular adsorption system in the treatment of hyperbilirubinemia in patients with liver failure[J]. Traum Crit Med, 2020, 8(2): 91-93, 96. DOI: 10.16048/j.issn.2095-5561.2020.02.08.

    许开亮, 雷鸣, 袁维方, 等. 双重血浆分子吸附系统治疗肝衰竭高胆红素患者疗效研究[J]. 创伤与急危重病医学, 2020, 8(2): 91-93, 96. DOI: 10.16048/j.issn.2095-5561.2020.02.08.
    [16]
    WIESNER R, EDWARDS E, FREEMAN R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124(1): 91-96. DOI: 10.1053/gast.2003.50016.
    [17]
    HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
    [18]
    JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61(5): 1038-1047. DOI: 10.1016/j.jhep.2014.06.012.
    [19]
    DU L, MA Y, ZHOU S, et al. A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system[J]. Sci Rep, 2021, 11(1): 1469. DOI: 10.1038/s41598-021-81019-8.
    [20]
    MA S, XIE Z, ZHANG H, et al. Characterization of an artificial liver support system-related vasovagal reaction[J]. Biomed Res Int, 2020, 2020: 6313480. DOI: 10.1155/2020/6313480.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (377) PDF downloads(42) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return